Journal article

Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model

D Yeo, N Huynh, JA Beutler, GS Baldwin, H He, M Nikfarjam

Journal of Investigative Surgery | TAYLOR & FRANCIS INC | Published : 2016

Abstract

Background: Pancreatic cancer continues to have a poor survival rate with an urgent need for improved treatments. Glaucarubinone, a natural product first isolated from the seeds of the tree Simarouba glauca, has recently been recognized as having anti-cancer properties that may be particularly applicable to pancreatic cancer. Methods: The effect of glaucarubinone on the growth and migration of murine pancreatic cancer cells was assessed by 3H-thymidine incorporation assay. The survival impact of glaucarubinone alone and in combination with gemcitabine chemotherapy was assessed using an immunocompetent orthotopic murine model of pancreatic cancer. Results: Glaucarubinone inhibited the growth ..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Cancer Institute


Funding Acknowledgements

This work was supported by grants from the Austin Hospital Medical Research Foundation, the Sir Edward Dunlop Foundation, and the National Health of Medical Research Council (NHMRC) of Australia (1020983, GSB; 508908, HH). Dannel Yeo is supported by Australian Rotary Health (The Ian Loxton Pancreatic Cancer Research PhD Scholarship). We also acknowledge the funding support of the Pancare Foundation (www.pancare.org.au) provided to develop novel therapies for the treatment of pancreatic cancer.